Global Study Report On Dermatophytic Onychomycosis (DO) - Current and Future Players

GlobalData has released its pharma report, “Dermatophytic Onychomycosis (DO) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing DO Market. The report identifies and analyses the key companies shaping and driving the global DO market. The report provides insight into the competitive DO landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts. 

To Read The Complete Report with  TOC :  http://www.marketresearchreports.biz/analysis-details/dermatophytic-onychomycosis-do-current-and-future-players

Scope

• Investigation of current and future market competition for DO
• Competitor assessment
• Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
• Strategic assessment of DO sector through market impact analysis, future market scenario and company analysis

To Buy a Copy Of This Report:  http://www.marketresearchreports.biz/analysis/169915

Reasons To Buy

• Gain a high level view of the trends shaping and driving DO Market
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market
• What’s the next big thing in the global DO market landscape? Identify, understand and capitalize

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Latest Analysis On EpiCast Report: Atopic Dermatitis-Epidemiology Forecast to 2022

Atopic dermatitis or atopic eczema is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Though the condition affects people of all ages, it is primarily common among infants and children (Bowcock and Cookson, 2004). Due to its chronic and relapsing nature, atopic dermatitis presents a global public health concern, with reported lifetime prevalence ranging between 10%–20% in children and 1%–3% in adults (Larsen and Hanifin, 2002). In general, the prevalence of atopic dermatitis is increasing worldwide, with high prevalence in western and developed nations compared with other parts of the world. However, recent trends demonstrate a gradual rise in prevalence in developing countries and plateauing prevalence in developed countries (Asher et al., 2006). Although atopic dermatitis is not life-threatening, it has a huge impact on economic burden and quality of life of individuals (Carroll et al., 2005). 

To Read The Complete Report with  TOC :  www.marketresearchreports.biz/analysis-details/epicast-report-atopic-dermatitis-epidemiology-forecast-to-2022  

GlobalData’s epidemiological analysis forecasts that prevalent cases of atopic dermatitis in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India) will increase from 132.28 million in 2012 to 132.71 million cases in 2022 at an annual growth rate (AGR) of 0.10%. In 2012, China and India combined contributed 83.04 million cases, comprising more than 60% of the total prevalent cases in the 9MM. 

GlobalData’s epidemiological forecast projects a substantial increase in the lifetime prevalent cases of atopic dermatitis in the 9MM over the forecast period (2012–2022). As GlobalData epidemiologists used steady prevalence proportions of atopic dermatitis over the forecast period, the growth in prevalent cases in each market can be attributed to the change in population demographics in the respective markets, especially in the younger age groups as they comprise the highest proportion of the prevalent cases. 

The forecast underscores the considerable psychosocial and economic burden inflicted by atopic dermatitis particularly among children. Governments in the respective markets should develop strategies to tackle the growing problem and direct appropriate interventions towards reducing various triggers inducing atopic dermatitis especially among young children (Williams et al., 2012). 

Scope

• The Atopic Dermatitis EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of atopic dermatitis in the 9MM. It includes a 10-year epidemiology forecast of atopic dermatitis prevalent cases segmented by age (in five-year increments beginning at age 0 and ending at ages 85 years and older), sex, and severity (mild, moderate, and severe) in the 9MM.

To Buy a Copy Of This Report:  http://www.marketresearchreports.biz/analysis/169914  

Reasons To Buy

• Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis market.
• Quantify patient populations in the global atopic dermatitis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for atopic dermatitis therapeutics in each of the markets covered.
• Identify the percentage of atopic dermatitis prevalent cases that are mild, moderate, and severe.

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Top Analysis On PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs. 

However, the market entry of entry of Novartis’ LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the drug’s efficacy in patients with heart failure with preserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drug to show efficacy in this largely underserved patient population. In addition, increased use of MRAs over the forecast period in all seven major markets (7MM) will contribute to the increase in the global CHF market size. 

To Read The Complete Report with  TOC :  http://www.marketresearchreports.biz/analysis-details/pharmapoint-chronic-heart-failure-global-drug-forecast-and-market-analysis-to-2022

Scope

• Overview of CHF, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized CHF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2011-2012 and forecast for ten years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CHF therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, including both pharmacological and non-pharmacological therapeutic approaches.
• Analysis of the current and future market competition in the global CHF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Market Model Features

An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Model only available with site and global license purchases.

Key Findings

• An increasing number of generic competitors present a significant barrier to growth in a market already heavily laden with generic drugs.
• The launch of Novartis’s LCZ-696, a new market entrant, will drive the overall growth of the CHF market in the 7MM during 2012-2022.
• To date, no drug has demonstrated sufficient efficacy in the HF-PEF segment of the CHF population in large-scale clinical trials. This unmet need presents a large opportunity for investment by drug developers.

Key Questions Answered in this Report

• Although the CHF market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the CHF market?
• The late-stage CHF developmental pipeline is sparsely populated, however, the early stage pipeline is more active and consists of novel pharmacological as well as non-pharmacological therapeutic approaches. Will the late-stage drugs make a significant impact on the CHF market? What are the earlier-stage novel, approaches that drug developers are pursuing?
• Although the incidence of CHF in the US has been relatively constant during the last decade, its prevalence has been gradually increasing. How will epidemiological changes impact the growth of the future market?

To Buy a Copy Of This Report:  http://www.marketresearchreports.biz/analysis/169913

Key Benefits

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
• Develop business strategies by understanding the trends shaping and driving the global CHF therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CHF therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global CHF therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Research Report On PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022 At Marketresearchreports.biz

Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. 

Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market. 

To Read The Complete Report with  TOC :  http://www.marketresearchreports.biz/analysis-details/pharmapoint-dermatophytic-onychomycosis-do-us-drug-forecast-and-market-analysis-to-2022

Scope

• Overview of DO, including epidemiology, etiology, general symptoms from infection, and disease management recommendations and guidelines.
• Annualized DO market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DO market.
• Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically new therapies with novel routes of administration.
• Analysis of the current and future market competition in the US DO market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Market Model Features

An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Model only available with site and global license purchases.

Key Findings

• Generic therapies are expected to pose as a considerable threat to upcoming topical therapies because of their shorter treatment duration.
• The first wave of new pipeline candidates will increase drug treatment rates as physicians begin to opt for more safer options for treatment.
• Individual compliance, patient co-morbidities, and insurance payers function as important considerations in assessing the treatment algorithm for every patient.

Key Questions Answered in this Report

• How big of an impact will topical agents have on the DO market? What do key opinion leaders think of this paradigm shift?
• What new product is expected to become the market leader during the forecast period? How will this impact the existing generic therapies?
• How will a change in the route of administration change the uptake of drugs in the US market?
• What are the primary unmet needs that exist in the market according to key opinion leaders?
• What alliance opportunities exist in this market for a company looking to tap into the DO market?

To Buy a Copy Of This Report:  http://www.marketresearchreports.biz/analysis/169912

Key Benefits

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the US DO market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US DO market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the US DO market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Global analysis : PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. 

GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. 

To Read The Complete Report with  TOC :  http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-global-drug-forecast-and-market-analysis-to-2022

Scope

• Overview of meningococcal disease, including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.
• Annualized meningococcal vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the meningococcal vaccine market.
• Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically serotype B vaccines and early stage infant and pentavalent vaccines.
• Analysis of the current and future market competition in the global meningococcal vaccine market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Market Model Features

An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Model only available with site and global license purchases.

Key Findings

• Country-specific epidemiology and serotype distributions heavily influence immunization recommendations and vaccine usage.
• Serotype B vaccines are expected to drive growth of the market space during the forecast period.
• Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.
• Government endorsements of new and existing vaccines are anticipated to dramatically influence market growth.

Key Questions Answered in this Report

• How large an impact will serotype B vaccines have on the meningococcal market? What do key opinion leaders think of these vaccines?
• What are the key vaccines for each age segment and country?
• Which meningococcal vaccines will face adoption challenges in the market? What is the projected uptake of new vaccines, such as Novartis’ Bexsero, over the forecast period?
• The developmental pipeline consists of vaccines that address serotype B protection and immunogenicity in infants. Which of these vaccines will attain high sales revenues during 2012-2022 and in which markets?
• What governmental and industry developments are likely to affect the vaccination rates in the markets researched? Which is the largest growth market globally?

To Buy a Copy Of This Report:  http://www.marketresearchreports.biz/analysis/169911

Key Benefits

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the meningococcal vaccine market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global meningococcal vaccine market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global meningococcal vaccine market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://mresearchreports.blogspot.com/

sal� K a k � � hreports.biz">sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Global Research Report On Life Insurance in Croatia, Key Trends and Opportunities to 2017

The report provides in depth market analysis, information and insights into the Croatian life insurance segment, including:

• The Croatian life insurance market’s growth prospects by insurance categories
• Key trends and drivers for the Croatian life insurance segment
• The various distribution channels in the Croatian life insurance segment
• Detailed competitive landscape in the life insurance segment in Croatia
• A description of the life reinsurance segment in Croatia
• Porter's Five Forces Analysis of the life insurance segment

To Read The Complete Report with  TOC :  www.marketresearchreports.biz/analysis-details/life-insurance-in-croatia-key-trends-and-opportunities-to-2017

Executive summary

The Croatian life insurance segment is small and competitive with the five leading companies accounting for a combined market share of 58.3% in 2011. Over the forecast period, insurers are expected to focus on minimizing costs to write new business, business strategies to develop new products and enhancing distribution channels to provide impetus for growth.

Scope

This report provides a comprehensive analysis of the life insurance market in Croatia:

• It provides historical values for Croatia's life insurance market for the report’s 2008–2012 review period and forecast figures for the 2012–2017 forecast period
• It offers a detailed analysis of the key sub-segments in Croatia's life insurance market, along with market forecasts until 2017
• It covers an exhaustive list of parameters, including written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, frauds and crimes, total assets, total investment income and retentions
• It analyses the various distribution channels for life insurance products in Croatia
• Using Porter’s industry-standard “Five Forces” analysis, it details the competitive landscape in Croatia for the life insurance business
• It provides a detailed analysis of the reinsurance market in Croatia and its growth prospects
• It profiles the top life insurance companies in Croatia and outlines the key regulations affecting them

Reasons to buy

• Make strategic business decisions using historic and forecast market data related to the Croatian life insurance market and each sector within it
• Understand the demand-side dynamics, key market trends and growth opportunities within the Croatian life insurance market
• Assess the competitive dynamics in the life insurance market, along with the reinsurance segment
• Identify the growth opportunities and market dynamics within key product categories
• Gain insights into key regulations governing the Croatian insurance market and its impact on companies and the market's future

To Buy a Copy Of This Report:  http://www.marketresearchreports.biz/analysis/169906

Key highlights

• The Croatian life insurance segment accounted for 25.6% of the country’s insurance industry gross written premium in 2012.
• The weak growth affected demand for all life insurance products, especially individual life, term life and marriage and birth polices, and consumer purchasing power weakened as a result of an increase in the unemployment rate and decline in per capita income. 
• Life insurers in Croatia employ various distribution channels to deliver insurance products. Agencies was the most preferred channel, accounting for 40% of the total life insurance written premium in 2012.
• The presence of a large number of foreign-owned companies is testimony to the country’s favorable regulations and competitive insurance industry.
• The increase in the elderly population will contribute to the growth of retirement-related products such as pension, annuity and superannuation coverage.

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/